STOCK TITAN

UBS ETRACS Alerian MLP ETN Series B Stock Price, News & Analysis

AMUB NYSE

Company Description

ETRACS Alerian MLP Index ETN Series B due July 18, 2042 (NYSE Arca: AMUB) is an exchange traded note (ETN) issued by UBS AG and traded on NYSE Arca. According to UBS communications, AMUB is part of the ETRACS platform of ETNs and is identified as the "ETRACS Alerian MLP Index ETN Series B" on the exchange. It is described as a senior unsecured note of UBS AG and is associated with the Alerian MLP Index, a trademark of VettaFi used under license.

UBS states that ETRACS ETNs, including AMUB, are senior unsecured notes issued by UBS AG that trade on NYSE Arca or NASDAQ and can be bought and sold through a broker or financial advisor. An investment in these ETNs is subject to the risk of loss of some or all of the investor’s principal and to the creditworthiness of UBS AG. UBS emphasizes that investors are not guaranteed any coupon or distribution amount under the ETNs, and that past performance is not necessarily indicative of future results.

For AMUB, UBS periodically announces coupon payments in public releases. These announcements identify AMUB by its NYSE Arca ticker and full name, and provide details such as coupon valuation date, ex-date, record date, payment date, coupon amount, payment schedule, and a stated current yield (annualized). UBS explains that the "Current Yield (annualized)" equals the current coupon amount multiplied by four, divided by the closing indicative value of the ETN on its coupon valuation date, rounded to two decimal places. UBS also notes that this current yield is not indicative of future coupon payments, and that there is no guarantee of any coupon or distribution.

The ETN is described as due July 18, 2042, which reflects its stated maturity date. As a senior unsecured note, AMUB represents a debt obligation of UBS AG rather than an ownership interest in underlying assets. UBS highlights that the securities related to these offerings are not deposit liabilities and are not insured or guaranteed by the Federal Deposit Insurance Corporation or any other governmental agency of the United States, Switzerland or any other jurisdiction.

UBS AG files a registration statement with the US Securities and Exchange Commission (SEC) for offerings of securities related to ETRACS ETNs. UBS indicates that investors should read the relevant prospectus, along with the applicable prospectus supplements and pricing supplements, to understand the terms of the securities and risk factors before investing in AMUB or other ETRACS ETNs. UBS notes that the applicable offering documents are filed with the SEC and can be accessed through the SEC’s EDGAR system.

Issuer context is provided through UBS AG’s SEC filings. UBS AG is a foreign private issuer that files annual reports on Form 20-F and periodic reports on Form 6-K. Its consolidated financial statements are prepared in accordance with IFRS Accounting Standards. UBS AG’s filings describe its capitalization, total debt issued, equity attributable to shareholders, and other capital and liquidity metrics. UBS also describes itself as part of UBS Group, which it characterizes as a global wealth manager and the leading universal bank in Switzerland, with diversified asset management solutions and focused investment banking capabilities.

UBS AG’s reports discuss topics such as capital management, risk management and regulatory developments. For example, UBS AG’s third quarter report outlines developments in Switzerland aimed at strengthening financial stability, including proposed changes to capital requirements for systemically important banks and potential deductions of investments in foreign subsidiaries from common equity tier 1 capital. These filings also describe UBS’s integration of Credit Suisse and the impact of regulatory changes on its capital position.

Within this broader framework, AMUB is one of multiple ETRACS ETNs referenced in UBS communications. UBS notes that ETRACS ETNs may be traded on NYSE Arca or NASDAQ and are subject to market risk and issuer credit risk. UBS urges investors to review the "Risk Factors" section in the applicable prospectus supplement for each ETRACS ETN, which would include AMUB, to understand the specific risks associated with the note.

UBS also clarifies that the Alerian MLP Index and AMZ are trademarks of VettaFi and that their use is granted under a license from VettaFi. VettaFi owns and administers the Alerian Index Series. This indicates that AMUB references an index administered by a third party under a licensing arrangement, as described in UBS’s public materials.

Key characteristics of AMUB based on available information

  • Instrument type: Exchange traded note (ETN) identified as ETRACS Alerian MLP Index ETN Series B.
  • Issuer: UBS AG, a foreign private issuer that files with the SEC and prepares consolidated financial statements under IFRS Accounting Standards.
  • Seniority: Described by UBS as a senior unsecured note, subject to the creditworthiness of UBS AG.
  • Exchange listing: Traded on NYSE Arca under the ticker symbol "AMUB," as stated in UBS’s coupon announcements.
  • Maturity: Due July 18, 2042, as indicated in the ETN’s full name.
  • Coupon announcements: UBS periodically announces coupon payments for AMUB, including coupon valuation dates, ex-dates, record dates, payment dates, coupon amounts, and a current yield (annualized) calculation.
  • Risk disclosures: UBS emphasizes the possibility of loss of principal, the absence of any guarantee of coupon or distribution amounts, and the lack of deposit insurance or government guarantees.
  • Index reference and licensing: Associated with the Alerian MLP Index, with Alerian MLP Index and AMZ identified as trademarks of VettaFi used under license; VettaFi owns and administers the Alerian Index Series.

According to UBS’s materials, investors considering AMUB should consult the relevant prospectus, prospectus supplements and pricing supplements, as well as the "Risk Factors" section, for detailed terms and risk information. UBS notes that its registration statement on Form F-3 and related documents filed with the SEC govern offerings of ETRACS ETNs.

Stock Performance

$—
0.00%
0.00
Last updated:
+3.9%
Performance 1 year

UBS ETRACS Alerian MLP ETN Series B (AMUB) stock last traded at $21.52. Over the past 12 months, the stock has gained 3.9%.

Latest News

UBS ETRACS Alerian MLP ETN Series B has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. View all AMUB news →

SEC Filings

UBS ETRACS Alerian MLP ETN Series B has filed 5 recent SEC filings, including 4 Form 424B2, 1 Form 424B3. The most recent filing was submitted on April 2, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AMUB SEC filings →

Financial Highlights

UBS ETRACS Alerian MLP ETN Series B generated $47.7B in revenue over the trailing twelve months, and net income was $3.6B, reflecting a 7.5% net profit margin. The company generated $24.6B in operating cash flow.

$47.7B
Revenue (TTM)
$3.6B
Net Income (TTM)
$24.6B
Operating Cash Flow

Upcoming Events

Short Interest History

Last 12 Months

Short interest in UBS ETRACS Alerian MLP ETN Series B (AMUB) currently stands at 3.1 thousand shares, up 12.5% from the previous reporting period, representing 0.1% of the float. Over the past 12 months, short interest has decreased by 14.8%. This relatively low short interest suggests limited bearish sentiment. The 5.4 days to cover indicates moderate liquidity for short covering.

Days to Cover History

Last 12 Months

Days to cover for UBS ETRACS Alerian MLP ETN Series B (AMUB) currently stands at 5.4 days, down 9.1% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 42.4 days.

Frequently Asked Questions

What is the current stock price of UBS ETRACS Alerian MLP ETN Series B (AMUB)?

The current stock price of UBS ETRACS Alerian MLP ETN Series B (AMUB) is $21.521 as of April 2, 2026.

What is the revenue (TTM) of UBS ETRACS Alerian MLP ETN Series B (AMUB) stock?

The trailing twelve months (TTM) revenue of UBS ETRACS Alerian MLP ETN Series B (AMUB) is $47.7B.

What is the net income of UBS ETRACS Alerian MLP ETN Series B (AMUB)?

The trailing twelve months (TTM) net income of UBS ETRACS Alerian MLP ETN Series B (AMUB) is $3.6B.

What is the operating cash flow of UBS ETRACS Alerian MLP ETN Series B (AMUB)?

The operating cash flow of UBS ETRACS Alerian MLP ETN Series B (AMUB) is $24.6B. Learn about cash flow.

What is the profit margin of UBS ETRACS Alerian MLP ETN Series B (AMUB)?

The net profit margin of UBS ETRACS Alerian MLP ETN Series B (AMUB) is 7.5%. Learn about profit margins.

What is ETRACS Alerian MLP Index ETN Series B (AMUB)?

ETRACS Alerian MLP Index ETN Series B (AMUB) is an exchange traded note issued by UBS AG and traded on NYSE Arca. UBS describes it as a senior unsecured note under the ETRACS ETN platform, identified on the exchange as "ETRACS Alerian MLP Index ETN Series B" and due July 18, 2042.

Who issues the AMUB exchange traded note?

AMUB is issued by UBS AG. UBS states that ETRACS ETNs are senior unsecured notes of UBS AG and that an investment in these ETNs is subject to the creditworthiness of UBS AG, as well as the risk of loss of some or all of the investor’s principal.

On which exchange does AMUB trade and under what ticker?

According to UBS coupon announcements, ETRACS Alerian MLP Index ETN Series B trades on NYSE Arca under the ticker symbol "AMUB."

Does AMUB guarantee coupon or distribution payments?

UBS explicitly states that investors in ETRACS ETNs, including AMUB, are not guaranteed any coupon or distribution amount. UBS also notes that the current yield (annualized) shown in coupon announcements is not indicative of future coupon payments, if any.

How does UBS describe the risk profile of AMUB and other ETRACS ETNs?

UBS explains that an investment in ETRACS ETNs is subject to a number of risks, including the risk of loss of some or all of the investor’s principal, and that these securities are subject to the creditworthiness of UBS AG. UBS also notes that the securities are not deposit liabilities and are not insured or guaranteed by the FDIC or any other governmental agency.

What information does UBS provide in AMUB coupon announcements?

In public releases, UBS provides the AMUB ticker and full name, along with coupon valuation date, ex-date, record date, payment date, coupon amount, payment schedule, and a calculated current yield (annualized). UBS explains the formula for current yield and emphasizes that it is not a forecast of future coupon payments.

What index is associated with AMUB?

UBS identifies the note as the ETRACS Alerian MLP Index ETN Series B and notes that Alerian MLP Index and AMZ are trademarks of VettaFi, used under a license. VettaFi owns and administers the Alerian Index Series, which indicates that AMUB references an index administered by VettaFi under this licensing arrangement.

Where can potential investors find detailed terms and risk factors for AMUB?

UBS states that it has filed a registration statement, including a prospectus and supplements, with the SEC for offerings of securities related to ETRACS ETNs. It urges investors to read the relevant prospectus, prospectus supplement and pricing supplements, including the "Risk Factors" section, to fully understand the terms and considerations before investing in AMUB.